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Abstract
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and consequent over-
expression of Sp-regulated genes occur frequently in human cancers. This provides the rationale for development of
inhibitors of Sp TFs as cancer therapeutics. Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA
sequences, inhibits activity of Sp TFs and exhibits potent antitumor activity in experimental systems. However, clinical use of
MTM-A is limited by the severe toxicity of the compound. Here, we studied two MTM-A analogues, which had been
generated by genetically engineering of the MTM-A biosynthetic pathway, and evaluated their activity in human prostate
cancer in cell cultures and mouse models. The compounds, named MTM-SDK and MTM-SK, were highly effective in vitro
inhibiting proliferation of prostate cancer cells and transcription of Sp-regulated genes by blocking binding of Sp proteins
to the gene promoters When administered to mice, both compounds were well tolerated with maximum tolerated doses of
MTM-SDK and MTM-SK, respectively, 4- and 32- fold higher than MTM-A. After systemic administration, both compounds
were cleared rapidly from the bloodstream but maintained plasma levels well above the active concentrations required in
vitro for inhibition of Sp TF activity and cell proliferation. Consistently, MTM-SDK and MTM-SK inhibited transcription of Sp-
regulated genes in prostate tumor xenografts and exhibited potent antitumor activity in subcutaneous and metastatic
tumor xenograft models with no or minimal toxicity. Taken together, these data indicate that MTM-SDK and MTM-SK
possess significantly improved pharmacological and toxicological properties compared to MTM-A and represent promising
drugs for treatment of advanced prostate cancer.
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Introduction
Tumor initiation and progression are mediated by multiple
signaling pathways and the therapeutic benefits achievable by
targeting individual pathways may be limited [1]. Targeting the
sites of convergence of diverse regulatory cascades may represent a
more promising strategy for cancer treatment. Transcription
factors (TFs) are particularly attractive in this regard since they are
nodal points in signaling pathways and are frequently deregulated
in human cancers [1,2]. Aberrant expression or activity of the
members of the Sp/KLF family of TFs, like Sp1, Sp3 and Sp4,
occurs in many human cancers [3] Sp TFs bind to GC-rich DNA
elements (GC-box) in gene promoters, interact with components of
the basal transcriptional machinery, cooperate with other TFs and
are downstream effectors of multiple signaling pathways [3].
Several studies have demonstrated that Sp TFs have important
roles in the pathogenesis of human cancers and are promising
therapeutic targets [3,4,5,6,7,8,9,10,11,12,13].
Mithramycin A (MTM-A) is a natural polycyclic aromatic
polyketide produced by various Streptomyces species [14]. MTM-A
binds preferentially to GC-rich sequences in DNA, blocks
competitively the binding of Sp TFs and other GC-binding
proteins to GC-rich elements in gene promoters and inhibits
transcription of Sp regulated genes [15,16,17,18,19]. Inhibition of
Sp regulated genes is the major determinant of the biological
activity of MTM-A in experimental systems [20,21]. Clinical use
of MTM-A however, is limited because of the toxicity of the
compound [22]. Genetically engineering of the MTM-A biosyn-
thetic pathway has given the opportunity to generate new
analogues of MTM-A that might possess improved pharmacolog-
ical and toxicological properties [23,24,25,26]. Recently, two
compounds, named MTM-SDK and MTM-SK, were obtained
using the metabolic engineering approach [27,28]. MTM-SDK
and MTM-SK exhibited greater ability to block Sp1 binding to
DNA and cellular uptake compared to MTM-A. This led to
increased biological activity as inhibitors of Sp regulated gene
transcription and proliferation of cancer cells both in vitro and in
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for treatment of cancers with abnormal activity of Sp TFs.
In this study, we evaluated the activity of the MTM-A analogues
MTM-SDK and MTM-SK in experimental models of human
prostate cancer. Prostate cancer is the most common cancer and
the second leading cause of cancer death in men in western
countries [30]. Conventional management of prostate cancer
includes surgery, radiotherapy and androgen deprivation [31].
Despite the gradual increase in disease-free survival and quality of
life, metastatic dissemination is still the main cause of death for
prostate cancer patients [31]. Advanced prostate cancer is often
resistant to hormonal treatment and systemic chemotherapy has
limited efficacy [31,32]. Palliative therapy remains the main
option for many of these patients. Therefore, new therapeutic
approaches need to be implemented to manage metastatic prostate
cancer. The state of Sp TFs in prostate cancer has been poorly
investigated to date. However, we found evidence supporting a
role for deregulated activity of Sp TFs in initiation and progression
of prostate cancer. Many genes reported to be involved in prostate
tumorigenesis are regulated by Sp factors (see Methods S1; Table
S1, S2 and references therein). Compounds that interfere with Sp
TFs by different mechanisms have relevant activity in various
cancers, including prostate cancer [7,8,9,10,11,33,34,35,36,37,
38]. These considerations, along with bioinformatics analyses of
published gene expression datasets, led us to hypothesize that Sp
TFs could be relevant targets in prostate tumors and that the new
MTM-A analogues with improved pharmacological properties
might be useful for treatment of this disease.
Materials and Methods
Compounds and cell lines
Human prostate cancer PC3, DU145, 22Rv1 and LNCaP cells
were maintained in RPMI 1640 [39]. Normal human fibroblasts
were maintained in DMEM [27]. MTM-A, MTM-SK (EC-7072)
and MTM-SDK (EC-7073) were prepared as previously described
[27]. Stock solutions of the compounds (10 mM) were prepared in
sterile saline solution or DMSO and diluted in sterile saline
solution immediately before use [29]. For gene expression and
chromatin immunoprecipitation (ChIP) cells were treated with
100 nM of MTM-SDK and MTM-SK or vehicle for 24 h.
RNA and protein analysis
Total RNA from cultured cells and tumor tissues was isolated
and reverse transcribed as described [27,29]. Quantitative real-
time RT-PCR (qRT-PCR) was performed using ABI PRISM
7000HT Sequence Detection System and SYBRGreen PCR
Master Mix (Applied Biosystems) as described [29]. PCR primers
are shown in Table S3. GAPDH and B2M were used as internal
controls. Expression data were expressed as a percentage of
control gene expression as described [29]. End point RT-PCR was
performed as described previously using the SuperScript One-Step
RT–PCR system (Invitrogen) and gene-specific primers [27]. Cell
lysates were prepared from control and drug-treated cells and
proteins separated on SDS–polyacrylamide gels. Immunoblotting
was performed as described previously [27,40].
Chromatin immunoprecipitation (ChIP)
Cells were collected, cross-linked with formaldehyde and
processed following a modified EZ-ChIP kit protocol (Upstate
Biotechnology) as described [41]. Chromatin was immunoprecip-
itated with an antibody for Sp1 and normal mouse IgG as negative
control. DNA-protein cross-links were reversed and DNA was
purified from total cell lysates (input) and immunoprecipitated
fractions. qPCR was performed as indicated above. Primers for
ChIP analysis of the C-MYC and VEGF promoter are shown in
Table S3. The amount of bound DNA was calculated in reference
to a standard curve and expressed as percentage of input DNA
[41].
In vitro cell growth inhibition
Cell viability was determined using the MTT colorimetric assay
as described [27]. Cells were plated in 96-well plates and
incubated with vehicle or compounds for 24 and 72 h. Each
treatment was performed in triplicate and experiments were
repeated at least three times.
Animals and xenograft models
Athymic male nude mice (Balb c nu/nu, 6–8 weeks old) were
purchased from the Harlan Laboratories. Mice were maintained
under pathogen-free conditions with food and water provided ad
libitum and their general health status was monitored daily. All
protocols involving laboratory animals were conducted in
conformity with the institutional guidelines and in compliance
with national and international laws and policies. Experimental
procedures and study protocols have been reviewed and approved
by the Swiss Cantonal Veterinary Authority (Approval no. 05/
2011). To establish subcutaneous tumor xenografts, PC3 cells
(2610
6 cells) were inoculated in the flank of mice. For the
metastatic xenograft model, PC3 cells (0.6610
6) were injected
twice into the tail vein with a 24-h interval between injections.
Toxicity
Healthy CD-1 mice provided by the University of Oviedo
Animal Facility were treated with single or repeated IV injections
of MTM-SK, MTM-SDK and MTM-A. Each group consisted of
4 mice. For repeated doses, drugs were administered by IV
injections every two or three days for a total of 10 injections. Body
weight, deaths, changes in behaviour, motility, eating and drinking
habits, and any other sign of local or systemic toxicity were
recorded daily.
Pharmacokinetics
Healthy CD-1 mice were injected IV with MTM-SK (18 mg/
Kg) and MTM-SDK (2 mg/Kg). Blood was collected at five time-
points between 5 and 120 min. At each time point 3 mice per
group were analyzed. Plasma samples were diluted with 4 volumes
of acetonitrile, vortexed and centrifuged to eliminate any insoluble
precipitate. The supernatant was then used to measure MTM-
SDK and MTM-SK by LC-MS. Plasma levels were assessed after
intraperitoneal (IP) and IV injection of MTM-SK (18 mg/Kg) also
by HPLC-UV.
Gene expression analysis in tumor xenografts
To evaluate the effects on transcription in tumor tissues, mice
bearing subcutaneous tumours were treated with MTM-SDK
(1.2 mg/kg) and MTM-SK (8 mg/kg) or saline solution by IV
injection. Animals were sacrificed after 1, 3 and 7 days from the
injection. Tumors were immediately collected and snap frozen for
RNA isolation. qRT-PCR was performed as described above. At
each time point 4 mice were analyzed in each experimental group
and qRT-PCR performed in triplicate for each sample.
Antitumor activity
Mice bearing subcutaneous tumors were treated with com-
pounds or vehicle. Each experimental group consisted of 10 mice.
Drugs were prepared in sterile saline solution and given by IP
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sterile saline solution. Tumor size was measured with a caliper
twice a week. Data represent average 6 SD of 10 mice per group.
Antimetastatic activity
To evaluate the compounds ability to block metastatic tumor
growth, mice received tail vein injections of tumor cells to establish
lung metastasis. Then mice were treated with MTM-SDK
(1.2 mg/kg), MTM-SK (8 mg/kg) or sterile saline given by IP
injections every 3 days starting two weeks after the tail vein
injection of tumor cells. Two groups of untreated mice (n=3 per
group) were sacrificed after 1 and 2 weeks from the injection to
confirm implantation and growth of metastatic cells. Control and
drug treated mice (n=3 per group) were then sacrificed after 1 and 2
weeks from the beginning of the treatment. Lung tissues were
collected for qPCR analysis and histological examination after
H&E staining. Lung metastases were quantified using a previously
described qPCR based method [42]. Genomic DNA extracted
from frozen lung tissues was amplified with primer sets for unique,
conserved and species-specific regions of the human and mouse
genome. PCR was carried out using SYBRGreen qPCR Master
Mix [42]. The percentage of human cells in lung tissues was
determined in triplicate paired reactions for each animal using
standard curve of mixed human/mouse samples as described [42].
Data are mean 6 SD of 3 mice per experimental point.
Statistical analysis
All data are expressed as mean 6 SD. The IC50 were
calculated using SigmaPlot. Differences between experimental
groups were analyzed for statistical significance using unpaired
Figure 1. Inhibition of Sp regulated genes by MTM-SDK and MTM-SK in prostate cancer cells in vitro. PC3 cells were treated with 100 nM
of MTM-SDK, MTM-SK or vehicle (DMSO) for 24 h. A) Gene expression was measured by qRT-PCR. Data were normalized to B2M RNA level and are
presented as percentage of expression compared to vehicle-treated cells (control). Data represent the mean 6 SD from 3 independent experiments.
B) Binding of Sp1 to the promoters of C-MYC and VEGF in control and drug treated cells was determined by ChIP using an anti-Sp1 specific antibody.
DNA in input and immunoprecipitated fractions was quantified by qPCR with primers encompassing the Sp binding site in the gene promoters. Data
(mean 6 SD) from 3 independent experiments are expressed as percentage of input DNA in immunoprecipated fractions. *, P,0.01; **, P,0.001. C)
Level of Sp1, Sp3 and Sp4 mRNA was determined by RT-PCR in PC3 cells incubated with 100 nM of MTM-SDK, MTM-SK or vehicle for 24 and 48 h.
GAPDH was used as control. D) Protein level of Sp1, c-Myc, XIAP, and cyclin D1 was determined by immunoblotting in PC3 cells incubated with
100 nM of MTM-SDK, MTM-SK or vehicle for 24 and 48 h.
doi:10.1371/journal.pone.0035130.g001
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values#0.05 were considered statistically significant.
Results
MTM-SDK and MTM-SK inhibit expression of Sp regulated
genes in prostate cancer cells
Analysis of the current literature showed that many genes over-
expressed in primary and metastatic prostate cancer are regulated
by Sp TFs and are potential targets of the MTM-A analogues (see
Methods S1, Table S1, S2 and references therein). Applying
bioinformatics approaches to publicly available gene expression
datasets we found that genes with predicted binding sites for Sp
TFs in their promoters were frequently deregulated in prostate
tumors both at the early and advanced stages of disease, despite
the lack of direct evidence of over-expression of Sp TFs in these
tumors (Fig. S1). Furthermore, we found that many genes down-
regulated by MTM-SDK in an ovarian cancer cell line and
putative targets of Sp TFs were over-represented among genes up-
regulated in primary and metastatic prostate tumors (Fig. S1).
Therefore, we assessed the impact of the new MTM-A analogues
on transcription of Sp-regulated genes in prostate cancer cells. We
selected genes known to be over-expressed in prostate tumors and
involved in various aspects of prostate tumorigenesis like cell
proliferation, apoptosis and angiogenesis (Table S1). Prostate
cancer PC3 cells were treated with 100 nM of MTM-SDK,
MTM-SK or vehicle for 24 h and the effects on gene expression
were assessed by qRT-PCR. This dose was chosen on the basis of
our previous work in ovarian cancer cells [27]. Furthermore, we
verified that 24 h treatment at doses #100 nM was minimally
cytotoxic (#30% of reduction in cell viability; Fig. S2). Under
these conditions, treatment with MTM-SDK reduced mRNA level
of C-MYC, hTERT, VEGFA, C-SRC, CCDN1, CCNE1, XIAP, MCL1
and BIRC5 by $75% (Fig. 1A). As previously shown in ovarian
cancer cells [27], MTM-SK was slightly less effective than MTM-
SDK. The level of C-MYC, hTERT, VEGFA, C-SRC and CCDN1
mRNA was reduced in MTM-SK treated cells by 50–75%
compared to control cells, while XIAP, CCNE1, MCL1 and BIRC5
were minimally or not affected.
MTM-A and its analogues bind to GC-rich DNA elements and
prevent binding of GC-binding proteins like the Sp TFs to gene
promoters. To determine whether the effects on transcription were
due to inhibition of Sp binding , we measured the binding of Sp1
to the C-MYC and VEGFA promoter in control and drug treated
cells by chromatin immunoprecipitation. MTM-SDK and MTM-
SK significantly reduced binding of Sp1 to the C-MYC and VEGFA
promoter (Fig. 1B). MTM-SDK was more effective than MTM-
SK, in agreement with the gene expression data. As Sp proteins
can control their own transcription [3], we evaluated whether
MTM-SDK and MTM-SK affected their expression. Sp1, Sp3
and Sp4 are expressed in PC3 cells and treatment with the MTM-
A analogues reduced the mRNA level of Sp1, Sp4 and to a lower
extent Sp3 (Fig. 1C). Again, MTM-SDK was more effective
MTM-SK. Protein levels of Sp1 and Sp targets, like c-Myc, were
also reduced upon treatment with MTM-SDK- and MTM-SK in
agreement with mRNA data (Fig. 1D).
MTM-SDK and MTM-SK inhibit proliferation of prostate
cancer cells
Inhibition of Sp TFs has been shown to affect proliferation and
survival of cancer cells. We examined the antiproliferative effects
of MTM-SDK and MTM-SK in a panel of prostate cancer cell
lines representing androgen-dependent (AD) and androgen-
independent (AI) prostate tumors. LNCaP cells are androgen
receptor (AR) positive and depend on AR signaling. 22Rv1 are
AR positive but AI. PC3 and DU145 are AR negative and AI.
Growth of all the cell lines tested, independent of their AR state,
was strongly inhibited by both compounds, with MTM-SDK
being more effective than MTM-SK (Fig. 2). The IC50 values are
reported in Figure 2. Moreover, growth of prostate cancer cells
was inhibited by $50% at #100 nM of both drugs. Notably, the
drugs had no effect at these doses on normal human fibroblasts
(Fig. 2). Viability of normal fibroblasts was affected slightly only at
higher doses (,20–30% of inhibition at 500 nM). This difference
in sensitivity between normal and cancer cells was in line with our
previous data showing that normal fibroblasts were more resistant
than ovarian cancer cells to the induction of apoptosis when
exposed to MTM-SDK [27].
Toxicity of MTM-SDK and MTM-SK
Systemic toxicity is a major limitation to the clinical use of
MTM-A. Therefore, we assessed the doses at which MTM-SDK
and MTM-SK could be safely administered to mice upon both
acute and chronic administration. The maximum tolerated doses
(MTD) of MTM-SDK and MTM-SK after a single IV injection
were 4 mg/kg and 32 mg/kg, respectively (Table 1). The MTD of
MTM-SK for repeated treatment was 8 and 18 mg/kg using the
q2d610 and q3d610 schedule, respectively. The MTD of MTM-
SDK was 1.2 mg/Kg and 1.8 mg/Kg, respectively, when given
with the q2d610 and q3d610 schedule. We tested for comparison
MTM-A and found that the MTDs were 1 mg/kg and 0.5 mg/kg
for single and repeated (q2d610) administration, respectively.
Further dose escalation of both MTM-SK than MTM-SDK and
repeated treatment resulted in progressive loss of body weight and
other signs of severe chronic toxicity, including decreased mobility,
conjunctivitis and peripheral neuropathy. In conclusion, remark-
ably higher doses of MTM-SK than MTM-SDK compared to
MTM-A could be given safely both as single and repeated
injections to mice without signs of toxicity.
Pharmacokinetics of MTM-SDK and MTM-SK
Blood levels of MTM-SK and MTM-SDK were measured after
single IV injections at the dose of 18 and 2 mg/kg (Fig. 3). Both
compounds were cleared rapidly from the bloodstream with
similar overall kinetics. After 5 min plasma levels were about 20
and 0.7 mM for MTM-SK and MTM-SDK, respectively. After
1 h the levels of MTM-SK and MTM-SDK were approximately 1
and 0.1 mM, respectively. Thus, plasma levels of both compounds
were at or above the concentration required in vitro for cell growth
inhibition and suppression of Sp1 dependent transcription. Next,
we compared pharmacokinetics of MTM-SK following single IV
and IP injections. Beside the initial peak seen with the IV injection,
the kinetics following IV and IP administration were quite similar,
reaching comparable drug levels in the plasma within 15–30 min
and maintaining similar levels over the 2-h period of the analysis
(Fig. S3).
MTM-SDK and MTM-SK inhibit gene expression in human
prostate tumor xenografts
To determine whether the MTM-A analogues were able to
interfere with the activity of Sp TFs in vivo upon systemic
administration, mice bearing PC3 tumor xenografts were treated
with a single IV injection of MTM-SDK (1.2 mg/kg), MTM-SK
(8 mg/kg) or saline solution. Tumors were excised at 1, 3 and 7
days after the injection and RNA levels of selected Sp regulated
genes were measured by qRT-PCR. Expression of C-MYC,
hTERT, VEGFA, C-SRC, CCDN1, CCNE1, XIAP, MCL1 and
Mithralogs for Prostate Cancer Therapy
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MTM-SK at 24 h (Fig. 4). However, there was a difference among
the two compounds in the kinetics of recovery from transcriptional
inhibition. The effect of MTM-SDK lasted longer. Most genes
were still repressed by 30 to 50% after 3 days. Even after 7 days
VEGFA, C-SRC and XIAP were still significantly down-regulated.
The effect of MTM-SK was reversed more rapidly with most
genes returning to control levels within 3 or 7 days. Thus, both
drugs were effective in reducing transcription of Sp-regulated
genes when given systemically to mice, confirming the accumu-
lation of active drug concentrations in the tumor tissue.
Furthermore, the effect of MTM-SDK was more pronounced
and persistent compared to MTM-SK, consistent with in vitro data
on Sp1 binding and gene expression.
Figure 2. Antiproliferative effects of MTM-SDK and MTM-SK in prostate cancer cells in vitro. Prostate cancer cells (DU145, 22Rv1, PC3 and
LNCaP) and primary cultures of normal human fibroblasts (NHF) were incubated with the compounds for 72 h. Cell viability was measured by the
colorimetric MTT assay. Data are presented as mean 6 SD of triplicate samples of 3 independent experiments. IC50 for each cell type are reported in
the bottom panel.
doi:10.1371/journal.pone.0035130.g002
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xenografts
The anti-tumor activity of MTM-SDK and MTM-SK was
examined using subcutaneous tumor xenografts of PC3 prostate
cancer cells. PC3 cells are AI, highly tumorigenic and metastatic.
Thus, these cells represent a good model of advanced castration-
resistant prostate cancer. Mice bearing PC3 tumor xenografts
received MTM-SDK (0.6, 1.2 and 1.8 mg/kg, q3d610) and
MTM-SK (4, 8 and 12 mg/kg,) every 3 days by IP injections. The
IP administration was chosen as it is commonly used for prolonged
treatments with anticancer compounds. Furthermore, IV and IP
injections were nearly equivalent in terms of plasma levels and
pharmacokinetics. Doses and schedule of administration were also
based on the pharmacodynamic and MTD data described above.
The treatment was terminated when mice in control groups had to
be sacrificed due to excessive tumor burden. Drug-treated mice
were followed for another week after the end of the treatment.
Treatment with MTM-SDK and MTM-SK reduced tumor
growth (Fig. 5A–B). The difference between treated and untreated
mice was highly statistically significant at all doses tested. After the
treatment was discontinued, growth of the subcutaneous tumors
slowly resumed with a slightly faster kinetics in the case of the
lower doses of MTM-SK. This is in agreement with pharmaco-
dynamic data, indicating a faster recovery of gene expression after
MTM-SK treatment. Interestingly, however, minimal tumor
regrowth was seen in mice treated with the highest dose of
MTM-SK. Treatment with MTM-SDK and MTM-SK resulted
in slight loss of body weight, which was correlated with the dose
level but not statistically significant (Fig. 5C–D). No signs of acute
toxicity or local irritation at the site of injection were observed
during treatment. Two mice treated with the highest dose of
MTM-SDK (1.8 mg/kg) showed signs of toxicity (e.g., decreased
mobility, peripheral neuropathy) after multiple injections. These
mice were taken off treatment and were not included in the
assessment of antitumor activity. Since the same dose was given
safely to non-tumor bearing mice, the toxicity observed at this dose
could be due to the presence of the tumor or differences in mice
strain or sex.
MTM-SDK and MTM-SK inhibit growth of metastatic
prostate cancer
We were interested in determining whether treatment with the
MTM-A analogues was also effective in a metastatic model of
prostate cancer. To this end, we used an experimental lung
metastasis model to study the effects of the treatment on
disseminated human cancer cells in immunodeficient mice. PC3
cells were injected in the tail vein of mice and the growth of lung
metastasis was monitored by qPCR over a 4-week period [42]. A
group of untreated control mice was sacrificed after the first and
second week from the injection of tumor cells. At this time, the
lungs contained 0.015 and 0.135% of human cells, respectively,
confirming the implantation and proliferation of the injected
human cancer cells (Fig. 6A). Thereafter, mice received every 3
days IP injections of MTM-SDK (1.2 mg/kg), MTM-SK (8 mg/
kg) or vehicle . Groups of control and drug-treated mice were
sacrificed two days after the second and fourth injection and their
lungs examined for the presence of metastasis. At this time, control
mice contained 2.08% and 5.94%, respectively, of human cancer
cells consistent with the expansion of the metastatic foci in the lung
(Fig. 6A). Instead, mice treated with MTM-SDK had 0.14% and
0.09% and those treated with MTM-SK had 0.43% and 0.42% of
human cancer cells after the second and fourth injection,
respectively. Thus, the growth of disseminated human metastatic
cells was almost completely suppressed by the treatment. The
qPCR data were confirmed by histological examination of lung
sections taken at the end of the experiment (Fig. 6B). Multiple
metastatic nodules were detected in the lung of control mice, while
there were no metastases detectable by microscopic examination
of serial sections of lungs of the drug treated animals.
Table 1. Maximum tolerated doses of MTM compounds.
Single dose (mg/kg)* Repeated dose (mg/kg)*
q2d610 q3d610
MTM-SK 32 8 18
MTM-SDK 4 1.2 1.8
MTM 1 0.5 ND
*CD-1 mice received IV single injections of MTM-SK, MTM-SDK and MTM or
repeated injections of the compounds every two (q2d610) or three days
(q3d610) for a total of 10 injections. ND, not determined.
doi:10.1371/journal.pone.0035130.t001
Figure 3. Pharmacokinetics profile of MTM-SDK and MTM-SK
in mice. Mice (n=3/group) received a single IV injection of MTM-SK (A)
or MTM-SDK (B) and plasma levels were determined by LC-MS. Doses of
MTM-SK and MTM-SDK were 18 mg/kg and 2 mg/kg, respectively.
doi:10.1371/journal.pone.0035130.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35130Figure 4. Inhibition of Sp dependent transcription by MTM-SDK and MTM-SK in tumor xenografts. Mice (n=4/group) with
subcutaneous tumors were treated with a single IV injection of MTM-SDK, MTM-SK or sterile saline solution. Doses of MTM-SK and MTM-SDK were
8 mg/kg and 1.2 mg/kg, respectively. Tumors were harvested 1, 3 and 7 days after drug injection. Gene expression was assessed by qRT-PCR. Data
represent mean 6 SD of the transcript level normalized to B2M RNA and are presented as percentage of expression compared to control mice
receiving sterile saline solution. *, P,0.01; **, P,0.001.
doi:10.1371/journal.pone.0035130.g004
Figure 5. Antitumor activity of MTM-SDK and MTM-SK in subcutaneous prostate tumor xenografts. Mice with subcutaneous tumors
were treated with the indicated doses of MTM-SDK, MTM-SK or sterile saline solution (control) given by IP injections twice a week for five weeks
(q3d610). Tumor volume (A) and body weight (B) were measured twice a week. Results are expressed as mean 6 SD of the tumor volume in each
group. Arrows indicate start and end of the treatment. **, P,0.001.
doi:10.1371/journal.pone.0035130.g005
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Sp family transcription factors control many cellular processes
essential for development of human tumors [3]. Diverse strategies
have been explored in recent years to interfere with the activity of
Sp TFs including natural compounds and small interfering RNAs.
Aureolic acid derivatives, like MTM-A, are effective inhibitors of
Sp TFs [15,18,19,20]. These compounds bind to GC-rich DNA
and prevent the interaction of the TFs with GC-rich sequences in
gene promoters. In addition, since Sp TFs control their own
transcription, MTM-A reduces the level of Sp proteins, thus
reinforcing the effect on transcriptional activity [21,34]. Various
factors can influence the pharmacological and toxicological
properties of the aureolic antibiotics: affinity for GC-rich
sequences, association/dissociation kinetics to DNA, ability to
compete with Sp proteins for binding to DNA and cellular uptake
[17,20,27,43]. These biochemical and biophysical properties
ultimately determine the efficacy of this class of compounds as
Sp TF inhibitors and their specificity toward Sp regulated genes
and selectivity toward cancer cells [27]. Differences in metabolism
and tissue distribution could also contribute to distinct in vivo
pharmacological and toxicological profiles. Genetic manipulation
of the MTM-A biosynthetic pathway to generate new compounds
with an array of structural modifications may provide the means to
produce analogues more active and more suitable for clinical use
than MTM-A [23,24,25]. In the present study we investigated two
MTM-A analogues, named MTM-SDK and MTM-SK, obtained
using this metabolic engineering approach [27]. Recently we
showed that MTM-SDK and MTM-SK exhibited increased
potency as inhibitors of Sp TFs and as anticancer agents compared
to MTM-A in biochemical and cellular assays [27]. Furthermore,
MTM-SDK and MTM-SK exhibited relevant in vivo antitumor
activity in human ovarian tumor xenografts [29].
In this study, we investigated the pharmacological activity of
MTM-SDK and MTM-SK in prostate cancer cell lines and
prostate tumor xenografts. The two compounds were effective
inhibitors of the transcription of Sp1-regulated genes both in vitro
and in vivo. Toxicity studies revealed that MTM-SDK and MTM-
SK were well tolerated upon systemic administration in mice. The
MTDs for single injections of MTM-SDK and MTM-SK were,
respectively, 4- and 32- fold higher than that of MTM-A.
Repeated treatment with both compounds using two different
schedules of administration was also well tolerated. Using doses
and schedules of treatment that could be safely administered , both
compounds exhibited potent antitumor activity in subcutaneous
prostate tumor xenografts. Even at the lowest dose tested,
Figure 6. Inhibition of prostate cancer metastasis to the lung by MTM-SDK and MTM- SK. Mice were given PC3 by IV injection into tail
vein and then starting 3 weeks later received IP injections of MTM-SDK, MTM-SK or sterile saline solution twice a week for two weeks. The doses of
MTM-SK and MTM-SDK were 8 mg/kg and 1.2 mg/kg, respectively. A) qPCR assessment of lung metastasis. Control mice were sacrificed 1 and 2
weeks before treatment and thereafter control and drug treated mice were sacrificed at end of the first and second week of treatment. Results are
presented as mean 6 SD of the percentage of human cells relative to total mouse cells in the lung (n=3). Arrows indicate the time of drug injections.
B) Microscopic evaluation of lung metastasis. Lung tissue was collected from control and drug-treated mice at the end of the experiment and stained
with H&E for histological examination. Representative sections are shown (620). **, P,0.001.
doi:10.1371/journal.pone.0035130.g006
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tumor growth. Prolonged treatment was well tolerated also in
tumor bearing mice with minimal reduction of body weight. Only
at the highest dose of MTM-SDK there were signs of toxicity in
few animals at the end of the treatment. MTM-SDK and MTM-
SK were also very active in a metastatic prostate cancer xenograft
model. Although lung is not a primary site for prostate cancer, this
experimental model approximates the clinical situation of
advanced disease with multiple metastatic foci growing at ectopic
sites. Advanced prostate cancer is difficult to treat and the finding
that the MTM analogues arrested the expansion of metastatic foci
in the lung could be clinically relevant. The metastatic cascade
comprises several steps. This experimental model requires cancer
cells to survive in the bloodstream, extravasate, form micro-
metastasis and then expand into clinically evident macro-
metastasis. In our experiments treatment was initiated at the
stage when multiple micro-metastatic foci were present in the lung
of control animals [42]. MTM-SDK and MTM-SK were able to
block further expansion of the metastatic foci, leading to almost
complete arrest of their growth. The mechanisms underlying the
antimetastatic activity of the MTM-A analogues would need to be
investigated further. Various metastasis promoting genes involved
in multiple steps of the metastatic cascade are known to be
regulated by Sp1 [44]. Thus, it is likely that the effect depends on
the ability of the compounds to block expression of genes necessary
for implantation, survival and expansion of the metastatic clones.
We assessed pharmacokinetics and pharmacodynamics proper-
ties of the MTM-A analogues to guide the choice of dose and
schedule of administration for the antitumor activity assays. We
found that MTM-SK and MTM-SDK were cleared rapidly from
the bloodstream after IV administration according to a typical
exponential decay. The pharmacodynamic data suggest a rapid
uptake in cells and tissues that would compensate for the short
half-life in the bloodstream as indicated also by previous in vitro
studies [27]. With both compounds there was no evidence of
metabolites in the blood, indicating that the decay was due to
clearance rather than metabolism. IP injection, which was used for
antitumor activity assay, was equivalent to IV injection in terms of
plasma levels. In the case of MTM-SK, initial plasma concentra-
tions after IP administration were low, increased to reach a
maximum within 15–30 min and then rapidly decreased mimick-
ing the behavior seen after IV injection. The pharmacodynamic
analysis of the effect on Sp dependent transcription showed that
both compounds inhibited transcription at 24 h after injection.
Interestingly, there was a difference among the two compounds in
the recovery from the transcriptional inhibition. Most genes were
equally repressed at day 1 and day 3 in MTM-SDK treated mice.
Even at day 7 many genes were still significantly repressed. On the
other hand, the effect of MTM-SK on transcription was lost more
rapidly. This is consistent with the differences in DNA binding and
inhibition of Sp1 activity seen previously between the two
compounds in cell culture experiments [27]. Differences in affinity
and reversibility of the binding to DNA among the aureolic acid
derivatives could play an important part in determining the
differences in biological activity [17,27,43]. Other properties
might also be at play: cellular uptake and nuclear retention are
also different between MTM-SDK and MTM-SK [27]. It is
interesting that tumor growth also recovered more rapidly in
MTM-SK than MTM-SDK treated mice when treatment was
ended, again suggesting more rapid recovery from the effects of
MTM-SK. Thus, distinct properties of the two compounds could
impact on their ability to sustain inhibition of Sp dependent
transcription and tumor growth and could modulate as well their
potential toxicity. The faster recovery of the effects of MTM-SK,
which could be attributed to a less tight and more readily
reversible binding to DNA, might in fact be advantageous in terms
of limiting the drug’s potential toxicity. Indeed, there was a
significant difference between the doses of MTM-SDK and
MTM-SK that could be safely given to mice, although both
compounds were more tolerated and could be administered at
higher doses than the parent compound.
The activity of MTM-SDK and MTM-SK demonstrated here
in prostate cancer cell lines and prostate tumor xenografts is highly
encouraging. Along with previous data in other tumor types, these
results indicate that these MTM-A analogues could be good
candidates for treatment of cancers in which Sp TFs play an
important role in driving the disease. Recent studies also have
expanded the potential of Sp TF targeting compounds like MTM-
A as cancer therapeutics. MTM-A was shown to have synergistic
activity in combination with other anticancer drugs in various
experimental models of human cancers [21,34,45]. Furthermore,
genetic alterations (e.g., single nucleotide polymorphisms in gene
promoters [46,47,48] and chromosomal translocations leading to
the production of aberrant TFs [49]) that increase the risk of
cancer initiation and progression could determine increased
sensitivity of cancer cells to MTM-A. The availability of safer
MTM-A analogues, like those described here, could lead to
translation of these laboratory observations into clinical applica-
tions. In the case of prostate cancer, although there is no evidence
of over-expression of Sp TFs, numerous lines of evidence suggest
that Sp1 and other Sp TFs are important players. We found that
several Sp regulated genes are over-expressed in prostate tumors
(Table S1) and compounds that interfere with the activity of Sp
TFs have antitumor or chemo-preventive activity in this disease.
Furthermore, a bioinformatics analysis of gene profiling data from
prostate tumor samples at different stages of disease indicated the
involvement of Sp TFs in the transcriptional perturbations
associated with primary and metastatic disease (see Methods S1
and Fig. S1). Comparing the up-regulated genes in primary and
metastatic prostate cancers with the MTM-SDK down-regulated
genes identified in a previous gene profiling study [27], we found a
significant overlap suggesting that many genes deregulated in
prostate cancer are potential targets of this class of compounds
(Fig. S1). A similar approach could be used to identify other tumor
types potentially sensitive to Sp TF targeting strategies. Collec-
tively, these data provide further evidence of the relevance of Sp
TFs as therapeutic targets and of the potential of MTM-A
analogues as effective cancer therapeutics.
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